安樂工程公佈2025年全年業績 本公司擁有人應佔溢利增23.5%至1.670億港元

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 領先的機電工程與智慧城市的資訊及通訊科技服務供應商安樂工程集團有限公司(「安樂工程」或「公司」,連同附屬公司統稱「集團」)(股份代號:1977),今天宣佈截至2025年12月31日止年度(「年內」或「2025財政年度」)的全年業績,除淨利潤錄得增長,集團的手頭合約更再創新高,訂單額增長逾倍,為未來三年及往後的發展奠下穩固基礎。財務摘要- 本公司擁有人應佔溢利按年增23.5%至1.670億港元- 手頭合約增61.8%至178.787億港元,再創歷史新高,受惠於年内訂單額增長113.7%至129.136億港元- 新增維修保養合約涵蓋房屋項目、環保項目以及升降機及自動梯,合約額增51.4%至16.69億港元,鞏固經常性收入來源- 集團維持強健現金水平,銀行結餘及現金為10.208億港元,資產負債比率則由26.2%降低至2025財政年度的10.1%- 董事會已決議派付第二次中期股息每股2.9港仙;全年合共派息每股5.5港仙,較上年度増25.6%主席麥建華博士表示:「2025年見證了全球的重大變化,挑戰與機遇並存。集團穩步向前,以謹慎履行承諾作堅實基礎,不斷精益求精,更推動革新落到實處、投資提升技術及生產力,引領香港工程的卓越實力踏上環球市場。我們欣然宣布,集團實現了利潤增長,更創下歷史新高的手頭合約水平,並持續鞏固在國際市場的影響力。這些成就彰顯了我們在各個業務領域的綜合能力,對卓越品質的承諾,以及在先進工程技術方面的領導地位。」「憑著充裕的現金流支持,我們具實力適時開展更多工程項目,並在高價值商機出現時抓緊機會。我們將繼續保持靈活專注,積極把握集團廣泛業務組合中的機遇,透過持續提升我們具競爭力的優勢,並強化應用創新解決方案,以提升工程品質、安全和表現。我們深知為客戶堅定不移地履行承諾,是贏得他們信任及維繫持久夥伴關係的基礎。秉持『重承諾、慎履行、獻成果』的座右銘,我們將繼續為客戶、股東、供應商和其他持份者創造最高利益,同時為我們所服務的社區作出貢獻。」業務回顧:屋宇裝備工程- 此業務板塊繼續成為集團最大的收益來源,收益達32.79億港元。- 手頭合約創下歷史新高,達82.97億港元,於2025財政年度新簽合約增長一倍達64.70億港元。集團在跨多專業的綜合項目中擁有競爭優勢,並有賴在創新的機電裝備合成法和其他新工程技術方面的領導地位成功取得重要合約。- 憑藉策略性投資以加快創新,並在珠海和香港發展現代化製造設施,集團得以在機電裝備合成法和裝配式設計技術方面繼續領先同儕。- 集團通過成功取得物業管理牌照擴大業務以提供可橫跨整個建築週期的綜合解決方案。此涵蓋建造、維修保養、營運,以至長期的設施管理的新能力,開拓了潛在的收益來源,與核心服務互補優勢。- 透過不斷開發創新技術和優化營運,此業務板塊強化自身定位以維持在市場中的競爭優勢,同時探索東南亞其他市場的發展機遇。環境工程- 此業務板塊的手頭合約與新增訂單額創下歷史新高,分別按年增加86.9%及253.7%至80.94億港元及53.55億港元。同時,業務收益按年增加18.0%至15.91億港元。- 此業務板塊於年內維持積極參與投標,並成功贏得標誌性合約,包括合約額破紀錄的搬遷沙田污水處理廠往岩洞、馬鞍山污水泵房等工程項目。- 於慶陽市開立了合營企業,以拓展中國內地的營運及維修業務。- 探索在亞洲和中東地區的項目機遇,並將專業服務拓展至歐洲市場。資訊、通訊及屋宇科技(「ICBT」)- 業務收益維持在6.30億港元,手頭合約價值截至2025年末為8.52億港元,年內新增訂單額為5.23億港元。- 此業務板塊持續以DigiFusion品牌鞏固其在綠色及智慧屋宇解決方案的領導地位,有助打造更智慧化、更可持續的城市環境。- 持續憑藉安樂工程大廈作為平台以研發創新技術,並透過與中國內地及環球領先生產商的策略合作持續擴大技術能力,從而加強在多個範疇的能力以提供可擴大規模的高效解決方案。升降機及自動梯- 收益與新增訂單額分別按年增加11.0%至5.87億港元,以及增加3.2%至5.66億港元。- 集團位於美國的聯營公司Transel Elevator & Electric Inc (「TEI」)取得重大合約,在聳立於紐約時代廣場旁的地標性56層摩天豪華酒店內提供世界級垂直運輸系統。TEI亦將業務版圖拓展至美國東南部,進一步鞏固其市場地位。- 積極加強在英國的業務,並擴大在其他國際市場的網絡,強化在垂直運輸解決方案領域的全球發展的雄心。- 無機房升降機產品繼續在主要國際市場取得進展。- 南京工廠簡化了生產流程,擴大產品種類,並提高了整體產品質量。這些提升正好配合集團的環球視野,肯定其承諾,矢志提供可靠和高效的垂直運輸解決方案。有關2025年度業績詳情,請參閱已呈交香港聯合交易所有限公司的公告。關於安樂工程集團有限公司安樂工程集團有限公司成立於1977年,為領先的機電工程與智慧城市的資訊及通訊科技服務供應商,總部設於香港,業務遍及中國內地、澳門、美國、英國、德國、新加坡及馬來西亞。本集團為公共和私營機構提供跨專業綜合機電及技術服務,涵蓋屋宇裝備工程、環境工程、資訊、通訊及屋宇科技(「ICBT」),以及升降機及自動梯等四大業務板塊。本集團同時製造及向全球銷售升降機及自動梯,並與美國紐約最大獨立升降機及自動梯公司之一 – Transel Elevator & Electric Inc.(「TEI」)達成夥伴關係。本集團的聯營公司南京佳力圖機房環境技術股份有限公司(603912.SS)專門製造精密空調設備。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

多維驅動全域突破 海天味業2025年交出高品質發展成績單

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月26日,海天味業(A股:603288;H股:03288)發佈2025年年度業績報告,面對2025年複雜多變的市場環境,憑藉多元產品矩陣、高效運營體系、硬核科技創新,公司在行業變革浪潮中穩健前行,交出一份彰顯行業龍頭實力與高品質發展成色的優異答卷。財報資料顯示,2025年公司核心經營指標穩健增長,實現營業收入288.73億元,同比增長 7.32%。盈利能力同步提升,全年歸母淨利潤70.38億元,同比增長10.95 %;扣非歸母淨利潤68.45億元,同比增長12.81%;調味品主業毛利率41.78%,同比增加3.15個百分點;各項經營資料均創下歷史新高,盈利品質與增長動力雙雙亮眼,彰顯公司硬核實力。豐富的國民產品矩陣,構築多元增長格局豐富完善的國民級產品矩陣,是海天味業實現穩健增長的核心基石。在產品矩陣方面,海天圍繞用戶需求持續推進品類創新,構建起覆蓋全場景烹飪的一站式產品體系,全方位滿足不同消費群體的多樣化需求。得益于豐富的產品矩陣與優異的產品品質,2025年,公司醬油、蠔油、調味醬等核心品類保持穩健發展,分別實現營業收入149.34億元、48.68億元及29.17億元,同比增長8.55%、5.48%及9.29%,構成業務增長的“金字塔基座”。其中,海天醬油產銷量和市場佔有率已連續數十年位居全國第一,海天蠔油的市場佔有率也連續10年位居全國第一,憑藉優質口感與穩定品質,成為千萬家庭與餐飲機構的首選;公司調味醬已形成產品豐富、風味立體、場景多元的產品體系,涵蓋黃豆醬、香辣醬等具備廣泛消費基礎的大單品,同時亦有柱侯醬、海鮮醬、拌飯醬、香菇醬等適用不同烹飪方式的特色醬料,紫蘇醬、桂林風味辣椒醬等適合不同地域口味的風味醬料,以及蔥油拌麵醬、重慶小面調料等便捷化調味醬,有效滿足用戶需求。此外,為順應消費者對醋類產品的細分化需求,公司堅持「傳統醋+特色醋」的產品佈局,同時不斷推陳出新,推出有機醋、果醋等多元化產品,形成豐富多元的醋類產品體系,進一步彌補品類空白,擴大市場覆蓋面。截至2025年底,公司擁有7個十億級以上產品系列、超30個億級以上產品系列,產品矩陣的豐富度與完整性持續提升。其中,金標生抽、草菇老抽兩大產品系列已暢銷60餘年,味極鮮醬油、海天上等蠔油兩大產品系列連續10餘年實現單品年收入超10億元,成為支撐公司業績穩健增長的「壓艙石」,其市場認可度與用戶忠誠度持續處於行業領先水準。在保持核心品類穩健增長的同時,海天精准把握消費趨勢變化,持續培育新興增長點,不斷豐富產品矩陣的層次與內涵。報告期內,在領先行業的產品力支撐下,以有機和薄鹽為代表的營養健康系列產品實現營業收入同比增速達48.3%,成為拉動業績增長的新引擎;食醋和料酒業務持續發力,規模優勢和體系化能力逐步顯現,市場佔有率穩步提升,為公司長遠發展注入強勁新動能。​值得關注的是,依託供應鏈規模效應、技術研發與柔性生產三大核心壁壘,海天加速從“調味產品供應商”向“一站式風味解決方案提供商”轉型,深度佈局商用市場,實現To C與To B業務雙輪驅動。截至2025年底,公司已為眾多餐飲連鎖、食品工廠及全球頭部零售品牌提供商用調味品一站式解決方案,成為公司業績增長的重要支撐。堅持以用戶為中心,全域深耕驅動效率與價值雙升堅持以用戶為中心,持續優化運營效率與用戶價值,是海天味業保持行業領先地位的關鍵所在。面對消費渠道的多元化變革,海天立足用戶需求,通過數字化賦能傳統渠道、擁抱新興渠道建設、聯動餐飲及工業渠道,實現效率與價值的雙重躍升,進一步鞏固市場滲透率。在傳統渠道方面,海天依託覆蓋全國的終端網路,借助數字化行銷工具和服務模式創新,持續向下沉市場滲透,並延伸到最終用家和消費者,顯著提高了終端覆蓋品質與消費者觸達效率,同時,通過終端管理的精細化升級,讓存量網點煥發新活力。2025年線下渠道營業收入達257.60億元,同比增長7.85%。線上與即時零售等新興陣地,海天主動適應消費場景的變化,通過規範銷售秩序、強化專業運營,實現新興渠道的高品質發展;針對新興渠道的消費特性,公司還推出線上定制化產品,精准匹配消費群體的需求,逐步構建線上與線下協同互促的健康發展模式,2025年線上渠道增幅高達31.87%。在商用渠道方面,依託柔性供應鏈與「銷研產一體化」快速回應機制,海天為餐飲連鎖和食品工廠提供從通用產品到定制化的一站式調味解決方案,實現「3天打樣、15天交付」的高效回應,大幅提升了客戶體驗與合作粘性。目前,餐飲與工業渠道穩健發展,收入占比持續提升,正成長為公司專業增長的重要動力源,進一步拓寬了公司的增長空間。堅持科技立企與創新,驅動價值鏈全面升級堅持科技立企、創新驅動,是海天味業實現高品質發展的核心動力。作為調味品行業數字化轉型的先行者,公司全面擁抱AI時代,推動人工智能、大數據與傳統釀造技藝深度融合,在守護匠心工藝的同時實現提質增效,推動行業從「傳統釀造」向「智慧釀造」轉型升級。海天味業堅持每年將研發投入保持在營業收入約3%的水準,近十年研發投入累計超65億元,累計擁有各類專利超1,000項,形成了完善的研發體系與創新機制。2025年1月,海天高明生產基地獲得全球醬油釀造行業首家「燈塔工廠」認證,標誌著公司數字化轉型已躋身全球行業標杆,也印證了中國調味品企業在智慧製造領域的領先實力。此外,公司部署端到端供應鏈創新用例,將AI與大數據深度應用於研、產、供、銷各環節,實現全鏈條的數字化、智慧化升級。在數字化全面賦能下,海天供應鏈運營效率顯著提升,訂單準時足額交付率(OTIF)不斷提高,綜合成本穩步下降,充分彰顯智慧製造帶來的效率紅利與競爭優勢。受益於在數字化轉型與高品質發展方面的突出成就,海天味業屢獲殊榮。2025年,公司斬獲「CGF中國供應鏈數字化與可持續韌性發展案例」「全國製造業數字化轉型典型案例」等多項殊榮,得到行業與社會的廣泛認可。同時,由海天主導起草的國家標準《食品數字化工廠通用技術要求》正式發佈,填補了國內食品行業數字化工廠通用技術標準的空白,為食品行業數智化升級提供「海天範式」,充分彰顯了公司的行業帶動力與責任擔當。回望2025年,海天味業以穩健業績、多元佈局、硬核實力,在高品質發展之路上行穩致遠,進一步鞏固了行業龍頭地位。展望未來,公司將繼續堅守匠心、深耕主業,持續優化產品矩陣、深化科技賦能、拓展全球市場,以更優質的產品、更高效的服務、更強勁的創新力,守護中國味道、引領行業升級,書寫中國調味品企業全球化高品質發展的嶄新篇章。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Southwest Airlines CEO:開會不等於工作——他正採取行動,每週三至週五下午封鎖行事曆

(SeaPRwire) -   企業領導人正拉響警報:會議已經席捲一切,真正的工作反而被拋在腦後。而西南航空(Southwest Airlines)執行長鮑伯·喬丹(Bob Jordan)是最新就此現象發聲的人士——他主張許多領導人誤將頻繁開會等同於領導能力。 「剛開始擔任領導職務時,很容易將忙碌和開會與領導能力畫上等號,」喬丹在2025年12月《紐約時報》DealBook峰會的執行長座談會上表示。「……我相信我們都有同感,就是根本沒有時間做『實際工作』,反而把開會當成了工作本身。」 多年來,喬丹的解決方案越發簡單直接:保護自己的時間。2026年,他的目標是讓每週三、四、五的下午行程完全空白——禁止任何人在這些時段預約會議。 儘管他承認這種做法對某些企業高管而言可能聽起來「瘋狂」,但他指出,執行長被僱用是為了處理只有他們能做的工作——而當他們陷在一場接一場的會議中時,這種工作幾乎不可能完成。  「這樣你才能專注處理需要投入心力的事,思考當下最重要的議題,打電話給需要溝通的人,」喬丹補充道。 這種策略似乎開始見效。儘管2025年航空業局勢動盪,西南航空仍在2025年10月的季度財報中意外獲利。其股價年增約16.5%。 已聯繫西南航空(Southwest Airlines)請求進一步評論。 會議已成為員工與僱主共同的惡夢 喬丹並非唯一感到困擾的人。會議已成為員工與高管共同的痛點。 疫情期間,會議幾乎扮演了「情感支持」的角色——試圖彌補封鎖期間缺乏面對面互動的空缺。由於無需等待會議室空出,日曆迅速被排滿。 但根據2024年Atlassian的一項研究(訪調四大洲5,000名員工),如今近80%的人表示被海量會議與電話淹沒,幾乎沒有時間完成實際工作。約72%的會議被認為效率低落。 這種反彈促使越來越多高管積極刪減——甚至徹底取消——企業日程中的會議,有時還劃出完全無會議的日子。不過,部分專家警告,徹底取消會議可能危及員工對組織的歸屬感,長期反而可能適得其反。 「會議不需要全數驅逐,只有那些低效、浪費時間的才需要,」就業科技公司Employment Hero執行長兼共同創辦人班·湯普森(Ben Thompson)先前向本刊表示。 輝達(Nvidia)與摩根大通(JPMorgan Chase)如何應對會議氾濫 其他執行長也發展出各自的非傳統策略。 例如,輝達(Nvidia)執行長黃仁勳(Jensen Huang)不會與超過50名的直接下屬進行一對一會議。他表示,這麼做不僅會壓垮自己的日程,還會拖慢團隊解決問題、有效運作與維持透明度的能力。 「我們的公司設計講求敏捷——讓資訊以最快速度流動,讓員工憑『行動能力』而非『已知資訊』獲得授權,」黃仁勳去年在史丹佛大學演講時表示。 摩根大通(JPMorgan Chase)執行長傑米·戴蒙(Jamie Dimon)則採取更直接的方式。在2025年致股東信中,他敦促員工重新思考會議是否有召開的必要。 「這是另一個拖慢我們的例子:會議。消滅會議,」他寫道。「但如果真的要開會,必須準時開始、準時結束——且必須有人主持。每場會議都要有明確目的,並永遠附上後續行動清單。」 隨著摩根大通要求員工每週五天回辦公室,效率變得更加重要。戴蒙強調,會議必須獲得全神貫注。 「開會時不能打瞌睡,不能看郵件,」戴蒙在10月本刊舉辦的「最具影響力女性峰會」上重申。「如果你面前擺著iPad,看起來像是在讀郵件或收通知,我會叫你關掉那該死的東西。這是不尊重的表現。」 本文最初於2026年12月15日發表於.com。 更多領導力相關報導: 瑪麗·巴拉(Mary Barra)儘管掌管市值650億美元的汽車大廠通用汽車(General Motors),仍堅持親筆回覆「每一封」收到的信件 AI時代向所有執行長傳達訊息:適應或淘汰 花旗(Citi)執行長珍·弗雷澤(Jane Fraser)篤信巴菲特(Warren Buffett)處理職場衝突的黃金法則:「永遠、永遠不要在憤怒時回覆那封郵件」 本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Cursor CEO警告:氛圍編程將建立「不穩固的基礎」,最終恐致「系統崩潰」

(SeaPRwire) -   Cursor 或許利用人工智慧來協助程式設計師編碼,但請別稱之為氛圍編碼,執行長暨共同創辦人 Michael Truell 表示。 他解釋道,十年前,程式設計意味著在空白的文書處理器中輸入程式碼並手動編輯。但隨著生成式人工智慧的出現,這種類型的程式設計正迅速成為過去式。 「越來越多情況下,你可以從程式碼中退後一步,要求人工智慧為你執行端到端的任務,」Truell 在十二月的 Brainstorm AI 會議上說道。 然而,他補充說,程式設計師可能不想退得太遠,並指出人工智慧輔助編碼是有層次之分的。 什麼是氛圍編碼? 常被提及的術語「氛圍編碼」可能看似涵蓋了所有人工智慧編碼助理。實際上,它指的是業餘開發者或經驗不足的人工智慧使用者,試圖在不一定深入了解底層原理的情況下將想法實現。 「氛圍編碼指的是一種使用人工智慧進行編碼的方法,你幾乎閉上眼睛,完全不去看程式碼,只是要求人工智慧去為你建構東西,」他說。 Truell 將其比喻為在不知道地板下或電線佈線情況的情況下,就蓋起四面牆和屋頂來建造房屋。 他警告說,這種編碼方法對於希望快速模擬遊戲或網站的 AI 使用者來說可能很完美,但當涉及到更高級的程式設計時,事情有可能出錯。 「如果你閉上眼睛不看程式碼,讓人工智慧在搖搖欲墜的基礎上建構東西,當你加蓋一層又一層又一層又一層時,東西就會開始崩潰,」他說。 Cursor 有何不同——以及為何這很重要 相比之下,使用 Cursor,程式設計師可以將人工智慧直接嵌入到他們編寫程式碼的整合開發環境中。透過利用現有程式碼甚至整個程式庫的上下文,它通常可以預測下一行程式碼。該工具包含從多行自動完成到完整函式生成的所有功能。它還可以幫助程式設計師除錯並解釋錯誤。 儘管年僅 25 歲,Truell 對人工智慧編碼的看法具有相當的分量。他與其他三位麻省理工學院的畢業生在 2022 年將後來成為 Cursor 的專案創建出來。 自那時起,Cursor 已成為最受歡迎的編碼助理之一,根據 Bloomberg 報導,截至去年,其每日活躍用戶已超過 100 萬。根據 CNBC 的資料,自推出以來,該公司已達到 10 億美元的年化收入,並聚集了 300 名員工。 Cursor 在 2023 年從 OpenAI 的 Startup Fund 獲得了第一筆 800 萬美元的投資。隨後,它又從一些矽谷最大的風險投資公司,包括 Andreessen Horowitz,籌集了更多資金。2025 年,該公司以 293 億美元的投後估值完成了一輪 23 億美元的融資。最後,截至本月,Bloomberg 報導稱,該公司據稱正在進行一輪融資,其估值將達到約 500 億美元。 Truell 表示,雖然氛圍編碼者可能像是在盲目飛行,但 Cursor 編碼助理卻能兩全其美,幫助其專業客戶深入探究程式碼的細節。 「但在那些你想要退後一步,要求人工智慧執行端到端任務的地方,你也可以這樣做,」他說。 此故事的一個版本最初於 2025 年 12 月 25 日發表在 .com 上。 更多人工智慧相關報導: 特朗普點名祖克柏、黃仁勳、艾里森加入科技顧問委員會——但排除馬斯克和奧特曼 華爾街確信人工智慧將殺死 SaaS。歷史和經濟學則另有說法 Cursor 的十字路口:一家 300 億美元人工智慧新創公司的迅速崛起與極不確定的未來 本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

Peter & Sons Launches in Ontario with Ellipse Entertainment

(AsiaGameHub) -   Forward-thinking iGaming studio Peter & Sons has expanded its footprint in the Canadian market by rolling out its full game portfolio in partnership with Ellipse Entertainment, a fully licensed operator based in Ontario. Ellipse Entertainment operates in compliance with the province's regulated gaming framework, and offers players access to its flagship platform HighFlyerCasino.com. The website pairs a wide-ranging collection of casino titles with a secure, smooth, fully regulation-aligned gaming experience that is custom made specifically for players in the Ontario market. Ontario has quickly emerged as one of the most progressive regulated iGaming jurisdictions across North America. Players throughout the province can now access a curated selection of Peter & Sons titles via HighFlyerCasino.com, bringing the studio's unique game worlds and gameplay mechanics to a growing community of Canadian players. Widely recognized for its catalogue of indie-inspired creations, quirky characters, and carefully crafted game worlds, Peter & Sons continues to break new ground in slot design and interactive entertainment. By joining forces with Ellipse Entertainment, a platform dedicated to delivering premium gaming experiences within a trusted regulatory environment, the studio is looking forward to building a long-term collaborative partnership in the Ontario market. Yann Bautista, Peter & Sons Founder and Commercial Director, said: “We are thrilled to launch our game portfolio with Ellipse Entertainment and bring our titles to players in Ontario. This region has quickly cemented its status as a key regulated market in North America, and HighFlyerCasino.com offers a robust platform for introducing our one-of-a-kind games to Canadian audiences.” Larry Galansky, founder of Ellipse Entertainment added: “We are glad to welcome Peter & Sons to our platform as we continue expanding the entertainment options available to our players. Their games are known for their distinct artistic style and immersive gameplay, and we are confident they will strike a chord with our user base.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

VeliTech debuts in Brazil at BiS SiGMA South America 2026

(AsiaGameHub) -   VeliTech is poised to make its inaugural appearance in Brazil at Stand i156 during BiS SiGMA South America 2026, which will be held in São Paulo from 6–9 April. The team is arriving with a double awards shortlist and a casino content offering crafted to attract attention. The company has been shortlisted in two key categories: Best Platform for VeliTech Best Gaming Experience for VeliPlay This recognition highlights two robust components of the VeliTech ecosystem. VeliTech has been shortlisted for the strength of its proven iGaming core platform, while VeliPlay is being acknowledged for the fast-paced, high-energy gameplay experience delivered via its crash and instant games. For its Brazil debut, VeliTech is placing casino content at the forefront. Taking center stage is VeliPlay, whose collection of crash and instant games is designed for speed, immersion, and repeat play. The lineup is further bolstered by Heaven of 7, the slot games provider within the VeliTech group, renowned for visually appealing titles and entertaining mechanics. Both studios have recently expanded their portfolios with new releases, including Pinball Rush from VeliPlay and Coin Up: Rise from Heaven of 7. Completing the showcase is VeliGames, VeliTech’s aggregation platform, recently recognized as the Industry Rising Star by SiGMA. With a single integration, it offers a broad content portfolio and robust back-office capabilities for operators. Together, VeliPlay, Heaven of 7, and VeliGames form a casino proposition aimed at helping operators differentiate themselves, combining adrenaline-fueled crash and instant titles, engaging slot entertainment, and aggregation technology that ensures content delivery is straightforward, scalable, and commercially effective. Mats Lundin, Chief Sales Officer at VeliTech said “Brazil is currently one of the most dynamic markets in iGaming, so making our debut at BiS SiGMA South America is a significant milestone for us. We’re heading to São Paulo with a content lineup designed to leave an impression, from fast-paced crash and instant games to engaging slots, all supported by the power of VeliGames aggregation. Being shortlisted for both Best Gaming Experience and Best Platform ahead of our first event in Brazil makes this milestone even more thrilling.” Visitors can meet the VeliTech team at Stand i156 to discover how connected technology and high-performing content can collaborate to develop a more robust casino offering for iGaming brands. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The filing will follow a standard review timeline.Taletrectinib (marketed as IBTROZI® in the U.S. and Japan) is a highly selective, next-generation oral treatment for patients living with advanced ROS1+ NSCLC.1 In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Following this filing to the EMA, additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories.Across Europe, nearly 400,000 people are diagnosed with lung cancer each year with NSCLC accounting for 80% of cases.2,3 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5“The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe. We look forward to working closely with the EMA during the review process with the goal of making this treatment available to appropriate patients who urgently need targeted options.”The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally.6,7 Results from a pooled analysis of the TRUST clinical program were published in the Journal of Clinical Oncology in April 20258, and Nuvation Bio anticipates near-term disclosure of updated data reflecting even longer patient follow-up, further building on the depth and durability of responses observed to date. Additionally, given the comprehensive nature of the taletrectinib clinical dataset and based on favorable feedback received at a pre-submission meeting with the CHMP Rapporteur and Co-Rapporteur, the accepted MAA will be considered to support full approval.“Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it in Europe and around the world.”In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.* Eisai’s licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.9 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5 About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain.10 The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.10,11About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 1About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.6,7About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)1WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full U.S. Prescribing Information.(1) Nuvation Bio Inc. IBTROZI (taletrectinib) US prescribing information. Available at: https://ibtrozipi.com/IBTROZI_taletrectinib-prescribing-information.pdf. Last accessed: March 2026(2) Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. Available here. Last accessed: March 2026(3) European Lung Foundation. Lung cancer. Available here. Last accessed: March 2026(4) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(5) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299. (6) ClinicalTrials.gov. A Study of AB-106 in Advanced NSCLC With ROS1 Fusion (NCT04395677). Available at: https://clinicaltrials.gov/study/NCT04395677 . Last accessed: March 2026(7) ClinicalTrials.gov. A single-arm Phase 2 study of taletrectinib in advanced ROS1-positive NSCLC (NCT04919811). Available at: https://clinicaltrials.gov/study/NCT04919811 . Last accessed: March 2026(8) Pérol M, A., et al. Taletrectinib in ROS1-positive non-small cell lung cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275(9) Global Data. Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData. Available here. Last accessed: March 2026(10) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(11) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comForward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding taletrectinib’s therapeutic potential and the urgent need for new therapeutic options for patients with advanced ROS1+ NSCLC in Europe, our expectations that the MAA filing for taletrectinib will follow a standard review with a decision in 1H 2027 and be considered for full approval, plans for additional filings for the U.K., Canada and other regions included in Eisai’s licensed territories, and expectations for near-term disclosure of updated data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Unlimited Super Free Spins in ELA’s Spring Release, Golden Bunny

(AsiaGameHub) -   ELA Games has unveiled Golden Bunny, a mid-volatility slot with an Easter theme. Ideal for the spring season, Golden Bunny combines a vibrant, hand-painted garden backdrop with streamlined, action-packed gameplay. The slot features a 5-reel, 3-row grid and uses a ‘Pays Anywhere’ system. At its core is an instant-reward mechanism where Egg symbols break open to show immediate payouts. Game progression revolves around Golden Eggs. Landing these symbols activates the regular Free Spins, which add extra prizes to the reels. At the same time, the eggs are collected in an Egg Basket located above the reels. As the basket gains value and expands, players progress toward the game’s key feature: Super Free Spins. When the basket overflows, this non-stop bonus round begins. The distinction here is that Super Free Spins eliminate the usual spin limits, continuing until the player hits the MINI, MINOR, MAJOR, or GRAND jackpot—revealed by the player in an interactive 'pick one' game. Marharyta Yerina, Managing Director of ELA Games, shared thoughts on the new title: “Golden Bunny is our spring 2026 release, and we aimed to pair our adorable bunny and playful theme with gameplay that gives players a clear goal. The ‘what you see is what you win’ aspect of the instant Egg rewards keeps the action going, but the real highlight is the Super Free Spins. Knowing the feature won’t stop until a jackpot is won builds great anticipation.” Golden Bunny will launch on March 26, 2026. Game Stats: Grid: 5×3 Paylines: Pays Anywhere Volatility: Mid (3/5) RTP: 93.93% / 96.01% Min Bet: €0.10 Max Bet: €50 Max Win Cap: x2000 Max Exposure: 100,000 This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

美麗田園2025年報重磅發佈!經調淨利潤大增41% 現金牛實力凸顯

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月27日,美麗田園醫療健康(02373.HK)正式發佈2025年度業績報告。年內,集團營收、利潤、現金流全方位高質量增長,以硬核業績凸顯行業龍頭的強增長韌性。集團盈利能力實現跨越式躍升。2025年,美麗田園集團總收入30億元,同比增長16.7%;毛利率提升至49.1%,同比提高2.8個百分點;經調淨利潤攀升至3.8億元,同比大幅增長41.0%,經調整淨利率達12.7%,提高2.2個百分點,盈利水平邁上新台階。公司持續顯現「現金牛屬性」。2025年集團經營活動產生的現金流量淨額達10.0億元,同比大幅增長25.4%;截至2025年12月31日,集團現金及類現金項目金額合計高達25.9億元,同比淨增41.6%,充沛且強勁的現金流為集團戰略投資與股東回報提供充足動能。這份營收與利潤大幅增長的亮眼業績,是集團「內生增長+外延並購」商業模式的成功體現,也是集團精益管理、提質增效及數智化賦能帶動整體效率提升的有力印證。「雙美+雙保健」模式賦能,盈利能力全面上揚作為核心基石業務,集團美與健康板塊逆勢高增,全年交出令市場矚目的亮眼答卷。2025年,美容和保健服務收入16.6億元,同比增長14.9%;毛利率提升1.2個百分點至41.9%;直營門店客流達172.4萬人次,同比增長23.2%;直營活躍會員增至14.6萬名,同比增長11.8%,直營活躍會員年均消費金額9738元,同比提升320元。直營活躍會員規模與年均消費實現雙增長。業績高質量增長的同時,集團錨定長期發展戰略。2025年,我們正式發佈超級供應鏈戰略,全面升級產品創研體系。未來,產品創研方式將全新拓展為全球精選、國際品牌合作、國際頂尖實驗室聯合研發三大模式並進,在傳承卓越品質的同時,注入創新動能。2026年2月,我們重磅宣佈與全球知名護膚品牌資生堂達成重磅戰略合作,在品牌影響力、服務體驗、科研共創等多維度深度攜手,開啟美與健康領域合作的新篇章。消費醫療兼具醫療價值屬性與消費彈性,是承載長期結構性機遇的優質賽道。美麗田園集團深耕消費醫療賽道,圍繞高端女性美與健康的核心醫療需求深度延伸佈局。過去16年,我們從0到1自建消費醫療能力,目前全國落地38家消費醫療機構,形成規模化佈局。2025年,消費醫療板塊整體收入13.4億,同比增長18.9%,占收入比例達到44.8%,成為重要的增長驅動力。具體來看,2025年集團醫療美容服務-秀可兒醫美逆勢增長,實現收入10.2億元,同比增長9.6%,毛利率大幅提升3.6個百分點至55.9%;客流10.2萬人次,同比增長13.1%,活躍會員攀升至3.6萬名,同比增長7.7%;活躍會員年均消費27,862元,同比增加490元。為進一步破局行業競爭、打造差異化核心優勢,秀可兒醫美精准錨定「專研抗衰」賽道,以「專家、專研、專注原生美」為品牌定位。2026年3月,Cellcare秀可兒品牌舉辦「專研抗衰」品牌升級發佈會,圍繞不同年齡層女性抗衰需求,打造 「初老抗衰、凍齡抗衰、逆齡抗衰」 的全週期產品藍圖,正式開啟秀可兒專研抗衰新時代。亞健康醫療服務--研源醫療作為集團增值業務迎來爆發式增長。2025年,研源醫療收入3.3億元,同比大增62.2%,收入佔比首次突破10%,成為集團業績增長的重要引擎;毛利率升至64.3%,同比提升6.1個百分點;客流量3.7萬人次,同比增長35.7%,活躍會員人數同比大增37.9%,活躍會員年平均消費28,032元,同比增加6287元。2025年,研源醫療旗下功能醫學板塊收入同比增長101%。在AI浪潮之下,我們將通過自研AI模型,深度融合精准檢測數據、專家診療路徑與臨床案例,實現「千人千面」的個性化診療方案與7x24全天候服務,以科技賦能醫療服務全面升級。研源醫療旗下女性特護板塊收入增長64%。我們將持續拓展服務版圖,構建「預防-治療-抗衰」女性健康醫療服務。並購整合戰略升級,以共贏之姿賦能行業發展中國「美與健康」市場坐擁萬億賽道規模,機遇與挑戰並存,合作共贏已經成為行業發展的必然趨勢。美麗田園主動投身行業整合進程,將投資並購上升為集團級核心戰略,以開放共贏的姿態攜手行業夥伴,共同推動美業高質量發展。2026年3月,集團重磅舉辦「尋找100位美業同行者」戰略投資暨行業賦能發佈會,宣佈將聚焦中國20個高線城市的美與健康服務機構,誠邀更多行業夥伴融入美麗田園生態體系,依託持續打磨精進的商業系統為行業夥伴提供全方位賦能提效,實現共生共贏。這一戰略佈局的底氣,源自集團過往逾30多起收並購項目中所積澱的深厚實戰經驗與可複製的整合方法論。2024年,集團完成對中國美容行業市占率第二大品牌奈瑞兒的收購,並通過系統化、精細化整合,實現奈瑞兒收入和利潤雙提升。2025年,奈瑞兒單店收入從收購前的575萬提升至810萬、經調淨利率從6.5%大幅提升至10.5%,以亮眼的數據印證了美麗田園強大的並購整合能力,更形成了一套可複製、可延展的行業整合成功範式。2025年10月,美麗田園集團宣佈以12.5億元人民幣全資收購行業第三大品牌思妍麗100%股權。伴隨著思妍麗於2026年1月正式併入集團報表,我們將複製奈瑞兒成功經驗,充分發揮自身模式優勢和平台能力,為業績增長注入新動能。至此,三大品牌齊聚美麗田園集團麾下,市場佔有率實現跨越式提升,中國美容行業競爭格局重塑。重磅打造商業系統,構建企業可持續增長核心壁壘33 年深耕,美麗田園集團從美容服務逐步延伸至消費醫療,已成功建成面向高線城市女性的美與健康綜合服務平台。2025年,集團重磅打造美麗田園商業系統,從多維度構建企業可持續增長模式,為長遠發展築牢體系根基。客戶價值成長系統。通過精細化客戶運營體系,我們構建起覆蓋推廣、獲客、轉化、會員留存、價值提升、複購、裂變的全鏈路運營閉環,為客戶持續創造長期價值。強平台+多品牌系統。我們構建了「強平台+多品牌事業部」協同的組織體系,支撐多品牌、多業務高效聯動與協同發展。前台事業部聚焦市場與客戶,靈活作戰、快速響應;平台沉澱能力、輸出標準,讓協同貫穿業務全流程,有效提升運營效率與業務延展性,為多品牌有序擴張提供堅實組織支撐。並購價值成長系統。我們構建了「投資+整合+成長」全週期並購價值成長體系,通過持續積累行業獨特的投資數據、成熟的投前模型、精進的投中整合,全面提升投後價值,形成成熟的並購與賦能機制,可適配不同規模、不同業務的優質標的,真正實現「並購即融合、融合即增值」。數智化與AI系統。集團將構建數智化驅動的管理體系,深度賦能美麗田園商業系統,讓體系能力可落地、可複製、可迭代,成為集團穿越經濟週期、持續引領行業發展的堅實支柱。資本市場價值提升,持續釋放長期投資價值2025年3月,集團正式發佈三大舉措,圍繞股東結構優化、高分紅比例及管理層激勵,持續向資本市場釋放長期投資價值。股東結構優化方面,2025 年 8 月,原PE股東中信產業基金正式退出主要股東行列,同步引入優質長期戰略投資者,股東結構進一步夯實。分紅方面,2026年董事會提議延續高分紅比例,將2025年歸母淨利潤的50%用於分紅,派發每股0.72港元,同比增長38.5%,以真金白銀的回報持續強化股東回報,彰顯企業對自身發展的堅定信心。管理層激勵方面,2025年,集團將未來三年收入及利潤目標與股權激勵深度綁定,首年業績目標已超額達成,激勵機制的有效性得到充分驗證。在此基礎上,公司進一步上調管理層股權激勵對應的三年業績目標,以更高標準統一公司與股東利益,在釋放增長潛力的同時,為投資者創造長期穩定回報。2025 年 11 月,公司成功納入 MSCI 全球小型股指數,進一步進入全球被動及主動型基金視野,吸引更廣泛的國際投資者關注。未來展望:三大超級戰略領航,錨定長期高質量發展美麗田園集團的長期願景是成為中國美與健康的領航者。站在行業整合與品牌升級的新起點,2025年11月,美麗田園正式發佈超級品牌、超級連鎖、超級數字化三大戰略,為未來高質量發展指明方向,擘畫長期發展藍圖。超級品牌,構建美與健康品牌矩陣。我們持續升級專業實力,打造超越客戶期待的體驗,重塑美容行業價值新空間。同時,積極參與並推動行業標準制定,將美麗田園的高標準上升為行業共識,提升消費者信任與品牌價值。超級連鎖,我們將發揮「雙美+雙保健」商業模式優勢,通過內生增長與外延並購雙輪驅動戰略帶動公司價值躍升。我們致力於打造20個收入過億的核心城市,同時構建自有供應鏈能力,融合全球精選與聯合專研,為中國高線城市女性提供兼具專業性、個性化、高品質的美容和消費醫療產品與服務。超級數字化,我們致力於打造數智化與AI系統基礎建設,構建數智化驅動的企業管理體系,打造數智引領的美與健康服務連鎖標杆企業。結語未來,美麗田園將繼續堅守「以客戶為中心」的初心,依託「美麗田園商業系統」,以「三大超級戰略」為指引,在不斷滿足高線城市女性對美與健康的多元需求的同時實現立體增長,推動中國美與健康行業的高質量發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

梅琳達· francês·蓋茨處理工作衝突有著原則:發言前等待 48 小時

(SeaPRwire) -   Melinda French Gates 分享了她處理職場衝突的秘訣。她選擇延後處理。 「如果我對你所做的工作不滿意,你會在 48 小時內收到我的消息,」French Gates 本週在接受 Bloomberg Business 的 Leaders with Francine Lacqua 播客採訪時說。「我不會馬上告訴你,因為我需要時間仔細思考。」 「如果我對某件事感到生氣,[我會這樣做來讓自己冷靜下來],」她補充說。「這是我的問題。」 她解釋說,這種做法與其說是為了壓制批評,不如說是為了以誠實、正直和恩典的方式提出批評。48 小時的時限也有其深意。如果時間過去了而沒有收到任何回饋,那就意味著員工做得很好。 「如果他們過了 48 小時的期限,他們就可以放心,他們的工作做得很好,」她說。「你不會在績效評估時遇到驚喜。」 這位億萬富翁慈善家數十年來一直在磨練這種做法。她從 2000 年到 2024 年一直擔任 Bill & Melinda Gates Foundation(世界上最大的私人慈善組織)的聯合主席,直到她於 2024 年卸任,這是在她與比爾·蓋茲離婚後約三年。 如今,French Gates 經營著自己的組織 Pivotal Ventures,這是一家她於 2015 年創立的投資和孵化公司,旨在促進美國女性和家庭的機會。作為與 Microsoft 創始人離婚協議的一部分,French Gates 獲得了 125 億美元,用於通過 Pivotal 進行慈善工作。她承諾在 2026 年之前每年額外捐贈 10 億美元,以增強全球女性的力量。 Melinda French Gates 的領導方法及其與其他高管的比較 Bloomberg 的 Lacqua 將 French Gates 的回饋方法稱為她的「領導超級能力」,這需要情緒紀律和坦誠。 「清晰就是善良,」French Gates 回應道,「因為我提供回饋是為了讓他們能夠真正成長並變得更好。」 French Gates 還將她的 48 小時回饋原則描述為在保持個人正直的同時,維護對方的尊嚴:「在開口之前,要恩典、周到。」 她的哲學與一些高管更具攻擊性的回饋文化相衝突。例如,Ray Dalio 將他的公司文化建立在他所謂的「徹底透明」之上,這是一種員工在各個層級都被期望提供未經篩選的實時批評的系統,幾乎所有會議都會被記錄下來以供事後分析。 Dalio 告訴 Business Insider:「如果你開始在智力上意識到,彼此之間真正誠實是一件值得珍惜的事情。」「這將建立信任。」 「有很多信任在其中,」創辦了全球最大對沖基金公司 Bridgewater Associates 的 Dalio 補充道。他甚至回憶起 Business Insider 曾有一次,一名初級員工給他發了一封電子郵件,將他在會議中的表現評為「D-」,因為他組織混亂。 因此,雖然 Dalio 偏愛即時和直白的批評,但 French Gates 則選擇更多的反思時間和尊重的語氣。 Microsoft 首席執行官 Satya Nadella 採取了略有不同的方法。當他接任 Microsoft 的領導職務時,他推動將「無所不知」的文化轉變為「無所不學」的文化——一種植根於謙遜、好奇心和心理安全感的文化。這是受到美國心理學家 Carol Dweck 的啟發,她以在動機和思維模式方面的研究而聞名。 Nadella 在 2016 年接受 Bloomberg 採訪時說:「如果你有兩個人,一個是無所不學的人,另一個是無所不知的人,那麼無所不學的人最終會勝過無所不知的人,即使他們最初的內在能力較差。」 儘管如此,French Gates 清楚地表示,她並不迴避困難的對話。 「我不介意衝突,」她告訴 Bloomberg。「我學會了以一種對我來說能保持我正直的方式來處理它。」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。

New “L00 Series” Train for the Seibu Railway’s Yamaguchi Line Begins Commercial Operation

The Frst New Leo Liner "L00 Series"TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of the first trainsets L00 Series ("Leo-kei") trains (4 cars per trainset, total 12 cars) ordered by Seibu Railway Co., Ltd. for its Yamaguchi Line, an automated guideway transit (AGT) system. Commercial operation of the first train began on March 27th. That same day, Seibu Railway held a commemorative ceremony for the start of commercial operation, attended by Tokorozawa City Mayor Masatoshi Onozuka and Higashimurayama City Mayor Takashi Watanabe.The new L00 Series are being manufactured at MHI's Mihara Machinery Works in Hiroshima Prefecture, and are scheduled to be delivered sequentially by FY2027. The seating arrangement has been changed from the bench seats used in the existing 8500 Series vehicles to longitudinal seats to increase transport capacity to BELLUNA DOME baseball stadium and Seibuen Amusement Park. To meet diverse passenger needs, wheelchair spaces, children's seats, and in-car information displays have been installed to enhance convenience.In addition, the new trains incorporate many unique specifications designed by MHI especially for AGT system vehicles, including aluminum bodyshells, the MHI bogie,(1), a ceiling duct air conditioning system,(2) and A-MVCS (Advanced Mitsubishi Vehicle Control System). The A-MVCS in particular, in addition to the vehicle control function, has monitoring and commissioning functions for each piece of on-board equipment, allowing it to flexibly meet the needs of railway operators.Further, a large glass window has been installed in the partition wall between the driver's cab and the children's seat, allowing children to enjoy the view from the front window and driver's seat, enhancing the sense of excitement for passengers.This AGT system utilizes rubber tires for a smooth ride and low noise. In addition, as a type of clean mobility with low CO2 emissions, the system has a reduced environmental impact, supporting the realization of a decarbonized and energy-efficient world. The adoption of vehicles that combine excellent design and environmental performance also enhances the impression of the surrounding facilities.Going forward, MHI Group will continue to strive for technological innovation, and through services that safely and comfortably transport people and goods, contribute to the development of public transport that supports the lives of people around the world.(1) A bogie developed by MHI for AGT systems. It is compatible with general rubber tire operation for AGTs.(2) A system that directs air through ducts behind the ceiling to provide air conditioning.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Modern Dental Group Announces 2025 Annual Results, Net Profit Surges 47.7% on Digitalization-Driven Operational Efficiency Gains

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

iGaming Real Talk Establishes Media Collaboration with Centurion FC

(AsiaGameHub) -   iGaming Real Talk is thrilled to reveal a new media partnership with Centurion FC, bringing exclusive behind-the-scenes content and detailed coverage to the global iGaming community. This collaboration seamlessly bridges the worlds of elite MMA and iGaming, delivering impactful cross-industry content for both fans and industry leaders. Centurion FC 28: Progredior will take place on April 8, 2026, at the Transamerica Expo Center in São Paulo as a flagship event of the renowned SiGMA World Tour.Happening right in the middle of BiS SiGMA South America—where top leaders from gaming, technology, and entertainment come together—this gives iGaming professionals an excellent opportunity to enjoy high-energy MMA fights and connect with key industry players. CFC 28 will broadcast live on XSPORT, which averages 10 million daily users with a potential reach of 150 million across Brazil, alongside international partner RYZ Sports Network. iGaming, tech, and entertainment companies now have the chance to secure exclusive sponsorship packages for this high-visibility event. Packages include premium octagon branding, weigh-in activations, full digital campaigns on Facebook, Instagram, and YouTube, VIP hospitality, and fighter brand ambassador opportunities. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

現代牙科集團公佈2025年全年業績 數碼化驅動運營效率提升 淨利同比大增47.7%

業績摘要:- 截至2025年12月31日止年度收益約為37.4億港元, 同比增加約11.1%。- 截至2025年12月31日止年度毛利率約為55.8% ;毛利約為20.8億港元,同比增加約15.9%。- 截至2025年12月31日止EBITDA 約為9.4億港元,同比增加約32.4%。- 本集團於截至2025年12月31日止純利約為6.0億港元,同比增加47.7%。- 截至2025年12月31日止每股基本盈利約為63.7港仙,相較去年同期增加約47.5%。- 董事會建議宣派截至 2025年12月31日止年度末期股息每股普通股15.0港仙。- 截至2025年12月31日止年度,本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案增加至約1,039,000件,較2024年同期增加32.7%,原因為更多客戶採用口腔內部掃描器。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 2026年3月26日,全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」,股份代號:03600.HK) 欣然公佈截至2025年12月31日止年度(「年度」) 業績。截至2025年12月31日止年度,在牙科行業數碼化趨勢持續的支持下,本集團的多維度策略及持續提升的營運效率及生產力,使其於本期間的收益、純利及EBITDA數字均創下紀錄新高。雖然期內宏觀經濟環境充滿挑戰,牙科手術的需求普遍疲弱,且貿易戰存在不確定性,然而仍然創下紀錄。本集團利用位於泰國、越南及中國內地的國際生產設施,積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動義齒行業的整合,使本集團進一步擴大其市場份額。我們持續的數碼轉型措施提升客戶及病人體驗的同時,進一步使本集團在競爭對手中脫穎而出,表現優於同業。本集團的相關基礎仍然穩固,並將全力以赴把握未來機遇。歐洲市場業務截至2025年12月31日止年度,歐洲市場錄得收益約18.9億港元,較去年增加約2.7億港元,此地理市場佔本集團收益總額50.5%。歐洲市場收益增加主要由於新產品的推出(例如數碼化義齒)及我們最先進的數碼化流程,推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅,範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器,本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過所建立,重點為教育及數碼化且非常鄰近客戶的牙科生態系統解決方案,積極從國際及本地競爭對手取得市場份額;透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己,為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務於截至2025年12月31日止年度,北美市場錄得收益約7.0億港元,較去年減少約5,570萬港元,此地理市場佔本集團收益總額約18.6%。我們在北美地區的大部分業務包括MicroDental Laboratories, Inc.及其附屬公司(「MicroDental集團」)在本地製造的高端產品。雖然2025年對主動美容治療的需求仍然疲弱,然而我們的中央化數碼流程及對區內廣泛生產單位的網絡讓我們為北美客戶交出更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地,繼續在應對美國關稅的不確定性時帶來更大彈性-此為將我們與競爭對手作區分的優勢。雖然進口產品線的數碼化帶動大型市場個案的增長,然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的銷售帶來緩慢增長。大中華市場業務截至2025年12月31日止年度,大中華市場錄得收益約6.2億港元,較去年減少約4,685萬港元,此地理市場佔本集團收益總額約16.5%。中國內地市場面對帶量採購政策及價格激烈競爭延長的逆境,而於2025年下半年情況開始穩定。此亦導致中國內地牙科診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意退出低利潤分部,並專注於中及高價值客戶,確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀,特別是在政府最新的採購相關措施中,預計(i)規範義齒價格及建立價格透明度,平衡中心點;(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量;及(iii)讓本集團從其龐大生產團隊中得益及根據顧客或客戶有效分配資源的能力。澳洲市場業務截至2025年12月31日止年度,澳洲市場錄得收益約2.9億港元,較去年增加約2,438萬港元,此地理市場佔本集團收益總額約7.7%。澳洲的收益錄得增長,反映牙科行業數碼化趨勢帶動大量新的數碼化產品,以及收購Digital Sleep的收益貢獻,但部分被相較於截至2024年12月31日止年度,澳元兌港元貶值2.4%所抵銷。透過我們不同的品牌(可提供境內及境外製造的產品),憑藉涵蓋從經濟及標準至優質/精品等的多種價位,本集團能夠有效地滲透整個澳洲市場。我們投資於本地產能,以為客戶提供更快捷的服務,並可供選擇產品之生產地。本集團為澳洲市場最大參與者之一並為市場內主要企業牙科團體的首選供應商。其他市場其他市場主要包括泰國、印度洋國家、馬來西亞、台灣及新加坡。截至2025年12月31日止年度,該等市場錄得收益約2.5億港元,較截至2024年12月31日止年度增加約1.8億港元。此地理市場佔本集團收益總額約6.7%。其他市場的收益增加主要由於新收購的Hexa Ceram帶來的收益貢獻所致。未來前景及策略全球宏觀經濟環境仍然不明朗,地緣政治的緊張局勢及關稅的潛在變動繼續營造不利環境。然而,本集團的生產遍及全球各地,而全球分銷網絡讓我們在面對該等挑戰時享有獨特優勢。有別於依賴單一國家生產的一眾競爭對手,我們的營運遍佈中國、越南及泰國(包括新收購的Hexa Ceram)等地,讓我們面對挑戰時能夠進退有據,靈活應變。此策略連同我們快速適應當地市場環境的能力,使本集團降低風險,同時把握各地區的新興機遇。牙科行業繼續展現卓越的適應力,在不可逆轉的人口趨勢下加以突顯,包括人口老化及人們對口腔健康的意識提高,持續帶動義齒的長期需求。本集團建基於2025年創記錄的表現而處於有利位置,能夠保持良好勢頭,同時進一步強化市場的領導地位。行業數碼化勢不可擋,加快義齒行業的整合。我們處於轉型的尖端,目前數碼化解決方案個案佔總銷量約35至40%。我們的中央化數碼工作流程、有關口腔內部掃描儀的夥伴關係、專有的解決方案及全球教育中心有助提升營運效率、縮短處理時間及提供卓越的客戶體驗。有關措施創造高進入門檻,並將於未來數年繼續擴大利潤及增加市場份額。在成功整合於2025年1月收購的泰國最大牙科實驗室Hexa Ceram及Digital Sleep Design(用於治療阻塞性睡眠窒息症的專利尼龍口腔矯正器)後,我們在東南亞地區的影響力及專業能力已經大幅提升。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地,讓我們在應對潛在的貿易及其他地緣政治風險時帶來更大彈性,同時支持區內快速交付。展望將來,本集團仍然致力透過多角度方針強化其全球領導地位。我們將繼續尋求具針對性的收購、合營企業及夥伴關係,以擴大及補充我們所提供的產品,特別是我們高增長的透明矯正器TrioClear,同時加強我們的分銷及銷售網絡。我們在大型生產設施、AI、自動化、研發及數碼創新方面的持續投資,使效率大幅增高,從而確保我們一直處於行業尖端。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問,專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材,例如牙冠及牙橋;活動義齒器材,例如活動義齒;及其他器材,例如正畸類器材、透明牙套、運動防護器及防鼾器。 現代牙科集團擁有多個備受稱許的全球品牌,包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及新西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務,令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 35,000 名客戶。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

JF SmartInvest Holdings Ltd Adjusted Profit Leaps 191.8% to RMB1.02 Billion ‘Technology + Investment Research’ Dual-Driver Strategy Delivers Remarkable Results, Overseas Expansion Ushers in a New Chapter of Globalisation

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

九方智投控股有限公司經調整溢利破10億大關 增長1.9倍「科技+投研」雙輪驅動成效顯著 海外佈局開啟全球化新局

摘要:- 總訂單金額約為人民幣3,955.0百萬元,較同期的約人民幣3,505.9百萬元增加約12.8%。- 總收益約為人民幣3,430.1百萬元,較同期的約人民幣2,306.0百萬元增加約48.7%。- 股東應佔溢利約為人民幣921.8百萬元,較同期的約人民幣272.4百萬元增加約238.5%。- 非香港財務報告準則下經調整年內溢利(剔除以股份為基礎的薪酬開支)約人民幣1,022.5百萬元,較同期的約人民幣350.5百萬元增加約191.8%。- 董事會建議派發末期股息約168.5百萬港元,即每股0.36港元(現金),建議末期股息須待股東於股東週年大會上審議及批准。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 九方智投控股有限公司(「九方智投控股」或「公司」;及其附屬公司統稱「本集團」或「我們」)欣然宣佈截至2025年12月31日止年度(「2025年」或「報告期內」)之綜合年度業績。報告期內,本集團踐行「科技+投研」雙輪驅動戰略,錄得良好業績表現。基於強勁的現金流與盈利表現,董事會建議派發末期股息每股0.36港元,連同已派發的中期股息,全年累計派息總額約407.4百萬港元,積極回報股東支持。財務表現強勁 盈利能力大幅提升報告期內,本集團持續推進產品創新、AI應用及投研能力建設,帶動整體業務穩健增長。年度總收益達人民幣3,430.1百萬元,同比增長48.7%;毛利達人民幣2,821.0百萬元,同比增長48.9%,毛利率維持在82.2%的高水平,反映本集團業務模式具備良好的規模效益及盈利質量。盈利表現方面,股東應佔溢利同比大幅上升238.5%至人民幣921.8百萬元。若剔除以股份為基礎的薪酬開支,按非香港財務報告準則計算的經調整年內溢利達人民幣1,022.5百萬元,同比增長191.8%,顯示公司戰略執行持續見效,並具備良好的市場應變能力。本集團始終重視股東回報,建議派發2025年度末期股息每股0.36港元,派息總額約168.5百萬港元。連同已派發的中期股息約238.9百萬港元,本集團2025年全年派息總額約為407.4百萬港元。穩健的派息政策充分反映集團充裕的現金儲備,以及對未來發展前景的堅定信心。持續優化產品矩陣 推動多元化服務體系建設報告期內,本集團持續構建多元化產品矩陣,圍繞不同客群需求不斷豐富產品組合。VIP產品(股道領航、超級投資家)穩步迭代,新增多款量化及AI產品,並上線7×24小時AI智能客服,進一步提升服務效率;直播體系亦全面升級,場次同比增加36%,日均總UV超過10萬。依託「硬件+AI+內容+服務」一體化方案,「易知股道」AI股票機於報告期內淨銷量超7.5萬台,用戶使用時長及黏性均保持良好水平;「九爻股」累計推出80餘款輕量化產品,將專業投研能力轉化為標準化產品,有效降低個人投資者參與門檻;「九方智投APP」則實現由工具向平台的戰略轉型,報告期內月活用戶同比增長超40%,30日留存率維持在50%以上,整體用戶黏性持續提升。此外,本集團進一步完善產品矩陣,推出「決策大師」及「星級服務」兩大新產品,填補中端產品空缺,跑通交易鏈路。其中,「決策大師」聚焦AI+題材、價投及量化三大投研模組,協助個人投資者提升自主決策能力;「星級服務」則聯動券商及合作夥伴,打造「工具—服務—交易」一體化生態閉環,報告期內服務用戶規模超過5萬。以科技創新為核心 全力邁向「投顧智能體2.0」本集團視創新和技術研發為核心驅動力,全速推進全面「數智化」戰略,深耕證券領域「人工智能+」應用,全力邁向「投顧智能體2.0」時代。報告期內,研發投入約人民幣356百萬元,研發人員達624人,較同期增長約42.8%;在人工智能、大數據及產品功能等領域共擁有軟件著作權及專利158件,同比新增22件。自研的「九方靈犀」大模型助手V3.0通過中國信息通信研究院大模型助手功能完備性測試,成為證券行業首個獲此認證的大模型應用。報告期內,該產品服務客戶約66.4萬人,累計服務達2,258萬次;智能投顧數字人「九哥」服務客戶約60萬人,累計服務超1,900萬次。公司亦推出診股智能體4.0智能體工具、AI小策問答助手,構建了覆蓋業務全流程的智能合規風控平台,逐步將AI能力深度賦能各大業務核心場景並形成規模化應用。為進一步強化技術基礎,本集團設立科技子公司九方智擎並入駐全國首個大模型創新生態特區「模速空間」,作為集團AI技術核心載體,搭載原生服務技術體系,推動AI在投研、投教、風控等場景深度落地。以深度投研為基石 堅持買方投顧 深化「1+N」投研體系本集團持續深化「1個研究所,N條業務線」投研體系,以九方金融研究所為投研中樞,推動專業能力滲透至業務全流程。研究所目前已建立以首席經濟學家肖立晟博士為核心,聯動4名專家、8名超級IP及128名專業人員組成的金字塔式團隊。截至報告期末,本集團擁有576名具備證券投資顧問資格及2,628名具備證券業資格的員工,專業團隊規模及結構均保持行業領先。報告期內,研究所完成上市公司、行業論壇及券商策略會等調研超300場,研究覆蓋約2,000家上市公司,並深度跟蹤其中1,500家;全年累計撰寫約1,200篇深度報告,並開發45套專題課程,總時長達2,000分鐘,持續鞏固買方投顧專業能力。多維全域流量運營 拓展業務增長新維度本集團以AI技術為核心驅動力,將MCN精細化流量運營定位為連接用戶與業務的核心樞紐,構建「公域MCN+私域+自有APP」三位一體、協同聯動的全域流量體系。技術層面,公司深度應用AIGC重構內容生產,從人工創作轉向「人機協同」,並搭建起「投放數據-模型訓練-運營自動化」的數據飛輪。報告期內,本集團持續鞏固線上短視頻直播平台的領先運營優勢,搭建多平台協同流量矩陣,打造多層次優質內容生態。同時創新探索AI股票機電商模式與APP應用市場,推動流量運營與產品特性深度適配。展望未來九方智投控股董事會主席及首席執行官陳文彬先生表示:「2025年,我們始終堅持『科技+投研』雙輪驅動策略。我們不僅實現了業績的跨越式增長,更成功引領行業邁向『投顧智能2.0』時代。基於人工智能與大數據技術,我們研發了九方智能投顧數字人、九方靈犀、九方智研等AI產品,實現了行業領先的創新實踐與場景應用,助力用戶完成從『認知提升』到『決策優化』的關鍵轉化。同時,我們將專業的投研能力轉化為觸手可及的輕量化服務,實現了由『工具向平台』的戰略轉型。我們貫徹理性投資、價值投資和長期投資理念,幫助客戶構建正確的投資觀。未來,本集團將聚焦四大戰略維度:第一,深化AI全場景賦能,加速投顧智能體迭代與C端商業化落地,驅動公司全面數智化轉型;第二,充分利用方德證券、方德資本牌照資源優勢,深化全球化戰略佈局,輸出九方核心模式,加速海外業務拓展,並推進數字資產相關牌照升級與戰略投資,完善數字資產基礎設施搭建;第三,強化產品力驅動多元協同,深化與券商等持牌金融機構的合作,構建涵蓋投前、投中、投後的服務閉環;第四,持續優化客戶經營體系,透過全域化流量佈局深挖流量價值,實現客戶長效留存。我們致力于让投資理財變得更簡單、更專業、提升投资理财的幸福感。」關於九方智投控股有限公司九方智投控股有限公司作為新一代股票投資助手,面向廣大個人投資者提供股票投資工具、證券投資顧問、投資者教育等服務,相繼推出股票行情軟件、AI股票機、股道領航、超級投資家、九爻股等產品。該公司通過「科技+投研」模式,基於人工智能(AI)與大數據技術研發九方智能投顧數字人、九方靈犀、九方智研等AI產品,實現行業創新實踐與場景應用。如有垂詢,請聯絡:金融公關(香港)有限公司電郵:ir@financialpr.hk電話:852 2610 0846傳真:852 2610 0842   Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

How to Choose the Right Savings Account for Your Money Goals in Singapore

SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

受邀參加中關村論壇!百望股份以Tax Swift打造全球貿易的”合規路由器”

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 近日,2026中關村論壇年會在北京隆重舉行。作為國家級科技創新交流合作平臺的重要參與者,百望股份受邀出席本次國家級科技創新交流盛會,並在"東盟創新合作發展論壇"中發表了重磅主題演講。論壇上,百望股份聚焦跨境貿易合規痛點,推介全球智能稅務合規平臺Tax Swift。它內置百望自研的AI稅務引擎、百望指數與國家適配器,依托覆蓋全球的稅務規則知識庫,動態監控、AI分析、自動更新,打造起全球貿易的"合規路由器",為國際經貿合作注入合規新動能。論壇聚焦科技創新,跨境合規成全球貿易核心命題2026年中關村論壇年會,是經國務院批准、以"科技創新與產業創新深度融合"為年度主題,由科技部、國家發展改革委、工業和信息化部、國家國資委、中國科學院、中國工程院、中國科協和北京市政府共同主辦。大會匯聚了100多個國家和地區的全球頂尖科學家、企業家及國際組織代表,上千名嘉賓共同搭建起中國與世界科技創新交流的橋梁。作為本次中關村論壇的重要平行論壇,東盟創新合作發展論壇聚焦中國與東盟科技創新協同、產業融合發展、跨境貿易便利化等核心議題,匯聚東盟各國政、產、學、研各界代表,交流研判破解區域經貿合作中的共性難題。在主題演講環節,百望股份圍繞著"AI賦能中企出海:構建全球化合規新底座"展開了深度分享。當前,全球貿易一體化進程不斷加快,跨國經營的業務蓬勃發展,但稅務合規難題始終是制約全球貿易高效推進的關鍵瓶頸。尤其是東盟這樣的活力經濟體,區域內各國經貿往來頻繁,跨境交易規模持續攀升,市場主體對於交易效率、交易合規有著更高的需求和更迫切的期待,而區域內各國稅務政策、技術標准的差異,卻成為了制約中國-東盟跨境貿易提質增效的重要因素。從實踐來看,國際貿易稅務合規難題呈現多元化、複雜化態勢:- 語言與格式壁壘凸顯,不同標准、規範讓企業票據解讀成本高、理解易出偏差;- 各國財稅政策碎片化嚴重,差異性的稅種、稅率、申報流程,讓企業難以精准掌握;- 技術標准不統一,系統接口、數據傳輸缺乏規範,各類操作繁瑣且效率低下;- 跨境交易鏈條長、涉及主體多,企業難以實現全流程風險檢測;這些難題不僅增加了企業跨境經營的成本,更成為制約企業融入全球產業鏈、拓展國際市場的關鍵瓶頸。百望股份的Tax Swift平臺,正是破解合規困境、保駕跨境貿易的全新技術創新,尤其為中國-東盟跨境貿易合規發展提供了高效可行的思路。Tax Swift重磅亮相,全鏈路一站式賦能國際貿易合規作為百望股份的深耕全球稅務合規領域、布局國際化市場的核心成果,Tax Swift一次適配,就可幫助企業構建起覆蓋"票據處理-納稅申報-風險管控"的全鏈路跨境稅務合規服務體系:一是全球AI全鏈路票據處理能力,可打破語言與格式壁壘。國際化引擎、發票引擎、稅務引擎與國家適配器,四重引擎自動協同運轉,完成智能算稅、智能識別等,一套架構適配全球業務場景。企業無需手動幹預任何細節,即可完成多語言、多幣種、多時區的票據管理工作,完美適配東盟各國票據規範與業務場景。二是全球AI一鍵申報,打通跨境稅務申報便捷通道。Tax Swift現已與20多國國稅局直連,全球稅務規則知識庫動態更新、AI分析引擎自動掃描規則變化,聯動發票識別引擎與全球交易計稅規則引擎實時響應,將全球申報工作壓縮成一個動作:一鍵登錄,自動填飽,實時同步狀態,可大幅提升東盟跨境貿易稅務申報效率。三是全球AI稅務顧問,提供全周期政策支撐。平臺內置超3萬條國際財稅規則,覆蓋200+國家稅種與費金,通過實時聯動發票引擎與稅務引擎,實現AI自動解讀、自動更新,及時識別和處置異常變化,幫助企業精准把握區域政策動態、規避合規風險,尤其針對東盟各國稅務政策的更新與調整實現實時響應。三大AI能力模塊的協同運作,為企業建立起全球合規洞察的能力,構築起清晰可控的合規管理邊界。當前,全球貿易格局深度調整,合規已成為企業跨境經營的核心競爭力,百望股份"貿易無國界、納稅有主權"的理念,精准契合了出海企業的合規需求。依托全球化戰略布局,百望股份持續推進TaxSwift產品迭代落地,自2025年8月啟動以來,產品已完成1.0版本全球電子發票布局,並在2026年加速海外數據中心與算力中心部署,加速東南亞、歐盟、中東等區域市場的拓展,向著建設覆蓋80+CTC國家的全球AI票稅合規平臺快速演進。而東盟作為百望股份全球化出海的先鋒陣地,憑借區域內旺盛的跨境貿易合規需求,成為 Tax Swift 落地應用的核心市場,已有眾多企業與百望股份達成深度合作,其中越南、新加坡、印度尼西亞等東盟國家的企業、高校更是與百望攜手,共同探索跨境稅務合規的數智化解決方案,讓 Tax Swift的技術能力與服務體系更好地適配東盟市場需求。依托中關村論壇及東盟創新合作發展論壇的開放平臺,更多國際嘉賓尤其是東盟各國代表,對百望股份的數智解決方案有了進一步了解。深耕財稅數智領域十餘年,百望股份已經累計處理發票數量逾260億張,對應交易總額高達1188.0萬億元,服務的納稅人識別號數量更是突破了9640萬家,這些豐富的實踐經驗與數據智能領域的深厚沉澱,贏得了與會嘉賓產生了高度關注與廣泛認可。未來,百望股份將持續深化Tax Swift平臺的迭代升級,重點打磨適配東盟市場的產品能力與服務體系,打造一流的全球稅務合規智能體平臺,進一步拓展全球服務範圍,幫助更多跨境經營的國際企業開拓發展、贏得未來! Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Fujitsu develops high-sensitivity, high-resolution infrared sensor to expand monitoring capabilities in defense and disaster prevention

KAWASAKI, Japan, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the development of a world-leading, high-sensitivity and high-resolution infrared sensor to expand monitoring capabilities in the defense and disaster prevention fields. This sensor is a Type-II superlattice (T2SL) infrared sensor with over 1 million pixels, capable of detecting both mid-wavelength infrared (MWIR) and long-wavelength infrared (LWIR) light. Its high-sensitivity allows it to clearly capture minute thermal differences of 0.05°C or less, enabling high-precision monitoring day and night. This over 1-megapixel dual-band T2SL infrared sensor is the first of its kind in the world.The newly developed technology boasts dramatically enhanced detection and identification performance, with applications spanning a wide range of fields. For example, when applied to optical sensor systems mounted on satellites or aircraft, it can contribute to the creation of new value across diverse areas, including early assessment of disaster situations and environmental monitoring.Integrating this sensor into monitoring devices for defense and disaster prevention enables accurate detection of thermal changes, such as identifying precursors to human activity or object movement, locating people during disasters, detecting early forest fires, and monitoring tsunamis. This contributes to improving information gathering capabilities and strengthening defense and disaster prevention. Additionally, by visualizing thermal distribution and changes over time with exceptional precision, the sensor is anticipated to play a vital role in tackling societal issues like infrastructure inspection and problems with analytical equipment, while also driving progress in scientific research.This technology was developed under contract as part of the "PROTOTYPE OF WIDE BAND AND HIGH RESPONSIVITY PHOTO-DETECTORS" from Acquisition Technology & Logistics Agency (ATLA), Japan Ministry of Defense, to which Fujitsu has completed delivery of the prototype sensor.Starting in fiscal year 2026, Fujitsu plans to leverage the manufacturing technology of this sensor to develop new products and market them for use in monitoring cameras.BackgroundIn the security sector, which underpins a safe and secure society, there is a demand for advanced sensing technologies that can detect various threats early and accurately capture their precursors. However, with the diversification of monitoring scenarios and the increasing complexity of targets, there is a need for even higher resolution sensors and improved identification capabilities through simultaneous detection of multiple wavelengths. The ATLA initiated a research prototype project to establish technology that enables target detection and identification over longer distances and wider areas than existing systems. Fujitsu, which has developed and mass-produced high-sensitivity infrared sensors, was awarded this project and has now successfully completed its development.Overview of the developed sensorInfrared sensors capture infrared radiation spontaneously emitted by objects with heat, visualizing their surface temperature distribution. Fujitsu has leveraged the characteristics of T2SL, a compound semiconductor with a superlattice structure that allows for material property control, to develop a unique dual-band sensor. The superlattice structure, where different semiconductor materials are layered at the nanometer (one billionth of a meter) level, offers high sensitivity, as well as excellent control over detection wavelengths and manufacturability. By selecting a combination of semiconductor materials with a large energy offset in their band structure (i.e., Type-II Superlattice, T2SL), it is possible to detect infrared light, which has lower energy than visible light.This sensor can detect MWIR and LWIR wavelength bands, with high-sensitivity capable of detecting temperature differences of 0.05°C or less. By simultaneously detecting two wavelengths with a single pixel, it can accurately detect and identify targets that would otherwise be obscured by background noise during detection with single-wavelength sensors. Furthermore, by advancing miniaturization of elements through the development of manufacturing processes and mounting technologies suitable for delicate T2SL materials, Fujitsu has achieved high-resolution with over 1 million pixels, enabling the capture of more distant targets.This infrared sensor, simultaneously achieving high-sensitivity, high-resolution, and dual-band detection, is suitable for monitoring applications in defense, disaster prevention, and other fields requiring high discrimination performance.Furthermore, this world-first technology from Fujitsu will drive further advancements in the sensitivity, multi-band and high-resolution capabilities of conventional infrared sensors, enabling a diverse range of product developments.Figure: Dual-band T2SL infrared sensor and example imagesAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Splinterlands and AtomicHub Renew WAX Bridge Partnership

(AsiaGameHub) -   Splinterlands has forged an official partnership with AtomicHub with the objectives of reviving and upgrading the WAX bridge, boosting visibility for its card NFTs, and simplifying cross-chain access for collectors and players. Splinterlands has previously supported WAX transfers, and its official documentation still lists WAX as one of its longest-standing partners. Good to Know AtomicHub has confirmed that it facilitates NFT trading across WAX, Vaulta, XPR Network, Polygon, Immutable, and Avalanche. Splinterlands’ cards have long been eligible for trading outside of the in-game marketplace, including on WAX via AtomicHub. The immediate priority is a more streamlined WAX bridge and improved discoverability for Splinterlands’ digital assets across marketplaces. Splinterlands and AtomicHub Revive a Familiar Connection Instead of building a new system from scratch, the two parties are building upon an existing prior link. Splinterlands and AtomicHub previously collaborated on a WAX bridge that allowed assets to be transferred for secondary market trading. The current plan is to modernize this existing setup and make transfers more seamless for users seeking additional places to buy and sell their cards. For Splinterlands, liquidity is the central focus. A trading card game’s economy functions more effectively when players can set clear prices for their cards, trade at a faster pace, and connect with buyers across multiple blockchains. AtomicHub provides a broader storefront for this effort, as it already operates across several blockchains and has a long track record in NFT trading. This partnership also aligns with Splinterlands’ core operations. Launched in 2018, the game runs on the Hive blockchain and revolves around player-owned cards that can be traded or rented out. Splinterlands also highlights tournament rewards and a card rental model in its official support materials, making access to external marketplaces far more relevant than it would be for a closed-game economy. Looking further ahead, both teams have plans that extend beyond the WAX blockchain. AtomicHub’s multi-chain support gives Splinterlands a path to reach a wider audience of collectors if deeper integrations are implemented. No timelines or additional blockchains have been detailed as of yet, so the most concrete deliverable for now is the upgraded bridge. FAQ What is the main goal of the Splinterlands and AtomicHub partnership? The primary goals of this partnership are to enhance liquidity for Splinterlands’ assets, upgrade the WAX bridge, and expand access to card trading across blockchain ecosystems. Did Splinterlands and AtomicHub work together before? Yes. Splinterlands previously operated a WAX bridge and has had a presence for its cards on AtomicHub for a long time. Why does liquidity matter for Splinterlands cards? Improved liquidity leads to simpler price discovery, more active trading, and more accessible entry points for players looking to build decks without overpaying. This is an inference based on how Splinterlands’ cards are traded and rented within its native ecosystem. Which blockchains does AtomicHub support right now? AtomicHub has stated that it supports NFT trading across WAX, Vaulta, XPR Network, Polygon, Immutable, and Avalanche. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.